Literature DB >> 3014480

Active immunization against varicella of children with acute leukaemia or other malignancies on maintenance chemotherapy.

R J Haas, B Belohradsky, R Dickerhoff, K Eichinger, R Eife, H Holtmann, O Goetz, U Graubner, P Peller.   

Abstract

Twenty-six patients with acute leukaemia and other malignancies susceptible to varicella were vaccinated with the Oka-strain live attenuated varicella vaccine during maintenance chemotherapy. All recipients showed no adverse clinical reactions. There was no spread of vaccine virus. Seroconversion was 94% in seronegative patients. Among those having low antibody titres before vaccination, a booster effect was demonstrable in 56%. None of the seroconverted recipients contracted varicella despite documented contact exposure. No case of herpes zoster occurred. The results suggest that, in immunocompromised children, live varicella vaccination has a protective effect against varicella infection which may result in a mortality rate of up to 7% in these patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3014480

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Varicella and varicella immunity in patients with lysinuric protein intolerance.

Authors:  M Lukkarinen; K Näntö-Salonen; O Ruuskanen; T Lauteala; S Säkö; M Nuutinen; O Simell
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

2.  Varicella vaccination in children with lymphoma and solid tumours.

Authors:  S Emir; M Büyükpamukçu; V Köseoğlu; G Hasçelik; C Akyüz; T Kutluk; A Varan
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

Review 3.  Guidelines on vaccinations in paediatric haematology and oncology patients.

Authors:  Simone Cesaro; Mareva Giacchino; Francesca Fioredda; Angelica Barone; Laura Battisti; Stefania Bezzio; Stefano Frenos; Raffaella De Santis; Susanna Livadiotti; Serena Marinello; Andrea Giulio Zanazzo; Désirée Caselli
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.